Abelacimab, a novel Factor XI/XIa Inhibitor, reduced bleeding vs Rivaroxaban in AF
Key Points: Previous studies have investigated the use of direct oral anticoagulants (DOACs) instead of warfarin for reduction of stroke risk in AF, but the risk... Read more.
Coronary Inflammation on CCTA as Predictor of Cardiac Events: the ORFAN Study
Key Points: Out of all patients who undergo a CCTA, the highest number of cardiac events occurs in patients without obstructive CAD. In patients with non-obstructive... Read more.
ESPIRIT: Intensive blood pressure control lowers MACE vs Standard Treatment
Key Points This randomized trial of 11255 patients in China with established CVD or at least 2 CVD risk factors but without a significantly reduced ejection fraction... Read more.
REPRIEVE Substudy: Pitavastatin reduces non-calcified coronary plaque in people with HIV
Key Points The REPRIEVE trial recently demonstrated that pitavastatin reduced major adverse cardiovascular events by 35% among individuals with HIV at low-moderate... Read more.
NOAH-AFNET 6: AHRE>24 hours associated with low stroke risk but more likely to develop AF later
Key Points This pre-specific subanalysis of NOAH-AFNET 6 found that those with long lasting atrial high rate episodes >24 hours were more likely to develop atrial... Read more.
ARTESIA: Apixaban reduces the risk of stroke in subclinical AF, with an increase in major non-fatal bleeding
Key Points This randomized trial of 4012 patients (median age ~77, mean CHA2DS2VASC ~4, ~65% male) with an implanted pacemaker, defibrillator, or cardiac monitor... Read more.
Novel siRNA targeting therapy lepodisiran results in a dose-dependent and sustained reduction in Lipoprotein(a)
Key Points: There are currently no approved targeted therapies for the reduction of Lp(a). In this Phase I study, a novel siRNA therapy (lepodisiran) was tested... Read more.
ARIES-HM3: Aspirin avoidance Is safe and reduces bleeding events in patients with HM3 LVAD on VKA
Key Points: Since the advent of novel HeartMate 3 LVAD technology with lower thrombotic risk, the clinical utility of continuing to add aspirin to the antithrombotic... Read more.
POCKET-COST-HF: Comprehensive Cost Disclosure improves cost-informed decision making
Key Points: Out-of-pocket costs for GDMT in HFrEF have risen substantially with the advent of novel effective therapies. However, there is limited information regarding... Read more.
Dietary sodium reduction significantly lowered BP in middle-aged to elderly adults
Key Points: Daily sodium intake remains high (on average ~3,500 mg/day), despite recommendations from the AHA and WHO to limit sodium intake to around 2,000 mg/day. ... Read more.
